{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:39:12Z","timestamp":1788439152035,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17H05104"],"award-info":[{"award-number":["17H05104"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K22719"],"award-info":[{"award-number":["19K22719"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Japanese Dental Science Review"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jdsr.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T01:23:16Z","timestamp":1632360196000},"page":"164-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pathogenesis and treatment of multiple myeloma bone disease"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4830-6274","authenticated-orcid":false,"given":"Masahiro","family":"Hiasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3997-7471","authenticated-orcid":false,"given":"Takeshi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdsr.2021.08.006_bib0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.leukres.2006.04.014","article-title":"Myeloma bone disease: pathogenetic mechanisms and clinical assessment","volume":"31","author":"Silvestris","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0010","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbo.2013.04.001","article-title":"Myeloma bone disease: pathophysiology and management","volume":"2","author":"Silbermann","year":"2013","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0025","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0030","series-title":"Bone tumors, diagnosis, treatment, and prognosis","author":"Huvos","year":"1979"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0035","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.htct.2019.01.012","article-title":"Oral health status of patients with multiple myeloma","volume":"42","author":"Feitosa","year":"2020","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0030-4220(88)90135-1","article-title":"Incidence of jaw lesions in 193 patients with multiple myeloma","volume":"65","author":"Lambertenghi-Deliliers","year":"1988","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0045","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1038\/bcj.2015.79","article-title":"Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma","volume":"5","author":"Ozaki","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0060","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1038\/sj.onc.1206315","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB\/p50) in myeloma cells","volume":"22","author":"Landowski","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0065","first-page":"57","article-title":"[The mechanisms of drug resistance via the interaction of myeloma cells with stromal cells]","volume":"73","author":"Kikuchi","year":"2015","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0070","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0075","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0080","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1200\/JCO.2002.20.1.353","article-title":"Human bone marrow myeloma cells express RANKL","volume":"20","author":"Sezer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0085","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2002-01-0148","article-title":"Immunocytochemistry reveals RANKL expression of myeloma cells","volume":"99","author":"Sezer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0090","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0095","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3816\/CLM.2009.n.085","article-title":"Serum levels of total-RANKL in multiple myeloma","volume":"9","author":"Jakob","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0100","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0105","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0110","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0115","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0120","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671.014k24_671_675","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0130","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2006-04-017087","article-title":"MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma","volume":"108","author":"Masih-Khan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0135","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0140","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s00774-008-0012-z","article-title":"Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production","volume":"27","author":"Abe","year":"2009","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-1119(03)00841-2","article-title":"Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology","volume":"321","author":"Nanes","year":"2003","journal-title":"Gene"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0155","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.4049\/jimmunol.173.8.4838","article-title":"Marrow stromal cells and osteoclast precursors differentially contribute to TNF-alpha-induced osteoclastogenesis in vivo","volume":"173","author":"Kitaura","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0160","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/leu.2015.229","article-title":"Blocking the ZZ domain of sequestosome1\/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo","volume":"30","author":"Teramachi","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2249.1993.tb05943.x","article-title":"Cytokines involved in the progression of multiple myeloma","volume":"92","author":"Merico","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0170","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0175","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0180","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0185","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0190","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2003-11-3811","article-title":"Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression","volume":"104","author":"Kumar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0195","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ajh.20639","volume":"81","author":"Bhatti","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0200","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.ejca.2006.02.017","article-title":"Angiogenesis in multiple myeloma","volume":"42","author":"Jakob","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0205","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0210","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.0007-1048.2002.03364.x","article-title":"Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma","volume":"116","author":"Iwasaki","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0215","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0220","doi-asserted-by":"crossref","first-page":"6361","DOI":"10.1038\/sj.onc.1210463","article-title":"An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma","volume":"26","author":"Takafuji","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1182\/blood-2009-08-237628","article-title":"Osteoclasts are important for bone angiogenesis","volume":"115","author":"Cackowski","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0230","doi-asserted-by":"crossref","first-page":"13366","DOI":"10.18632\/oncotarget.24351","article-title":"Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin(\u00ae) protein MP0250: a preclinical study","volume":"9","author":"Rao","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0235","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1038\/leu.2017.173","article-title":"Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma","volume":"31","author":"Richardson","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0240","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0245","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0250","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0255","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0260","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1080\/10428190701861686","article-title":"Novel anti-myeloma agents and angiogenesis","volume":"49","author":"Anargyrou","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0265","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","article-title":"Thalidomide\u2014a revival story","volume":"341","author":"Raje","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0270","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D\u2019Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0275","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S8756-3282(00)00445-2","article-title":"Biosynthesis and processing of cathepsin K in cultured human osteoclasts","volume":"28","author":"Rieman","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2012.11.005","article-title":"Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL\/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules","volume":"41","author":"Bolzoni","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0285","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/leu.2008.174","article-title":"Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma","volume":"22","author":"Breitkreutz","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0290","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1080\/10428190701648281","article-title":"Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma","volume":"48","author":"Giuliani","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0295","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bone.2010.06.016","article-title":"Osteoblast function in myeloma","volume":"48","author":"Roodman","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0300","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0305","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1158\/0008-5472.CAN-11-2067","article-title":"Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1","volume":"72","author":"Fowler","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0310","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2008.01065.x","article-title":"Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma","volume":"80","author":"Kaiser","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0315","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0320","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0325","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0330","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease","volume":"118","author":"D\u2019Souza","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0335","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0340","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0345","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1541-7786.MCR-16-0242-T","article-title":"EZH2 or HDAC1 inhibition reverses multiple myeloma-induced epigenetic suppression of osteoblast differentiation","volume":"15","author":"Adamik","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0350","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.emboj.7600067","article-title":"Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells","volume":"23","author":"Maeda","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0355","doi-asserted-by":"crossref","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0360","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0365","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0370","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jbmr.320","article-title":"The amazing osteocyte","volume":"26","author":"Bonewald","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0375","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0380","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0385","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/bcj.2011.22","article-title":"Myeloma cells suppress osteoblasts through sclerostin secretion","volume":"1","author":"Colucci","year":"2011","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0390","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1749-6632.2011.06196.x","article-title":"Sclerostin is overexpressed by plasma cells from multiple myeloma patients","volume":"1237","author":"Brunetti","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0395","first-page":"266","article-title":"Osteogenic inhibition in multiple myeloma","volume":"15","author":"Habibi","year":"2013","journal-title":"Cell J"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0400","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0405","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0410","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0415","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9 Suppl 4","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0420","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12185-019-02636-8","article-title":"JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM)","volume":"109","author":"Iida","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0425","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","article-title":"Biochemical and molecular mechanisms of action of bisphosphonates","volume":"49","author":"Rogers","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0430","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0435","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0440","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0445","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0450","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jos.2018.06.001","article-title":"Emerging anti-osteoclast therapy for rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2018","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0455","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0460","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0465","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0470","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00198-015-3335-3","article-title":"Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015","volume":"27","author":"Khan","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0475","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0480","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0485","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0490","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0495","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0500","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0505","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1185\/03007995.2016.1170005","article-title":"Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw","volume":"32","author":"Taguchi","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0510","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s00223-015-0045-y","article-title":"Impact of osteonecrosis of the jaw on osteoporosis treatment in Japan: results of a questionnaire-based survey by the adequate treatment of osteoporosis (A-TOP) research group","volume":"97","author":"Taguchi","year":"2015","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0515","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0520","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0525","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0530","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jcms.2015.03.039","article-title":"Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?","volume":"43","author":"Otto","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0535","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.43","article-title":"A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function","volume":"25","author":"Vallet","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0540","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","article-title":"MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts","volume":"110","author":"Vallet","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0545","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bjh.13056","article-title":"A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events","volume":"167","author":"Iyer","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0550","article-title":"Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management","volume":"15","author":"D\u2019Oronzo","year":"2019","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0555","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/jbmr.142","article-title":"Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo","volume":"25","author":"Chantry","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0560","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bjh.12835","article-title":"Sotatercept in patients with osteolytic lesions of multiple myeloma","volume":"165","author":"Abdulkadyrov","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0565","first-page":"1517","article-title":"Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies","volume":"24","author":"Raftopoulos","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0570","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0575","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0580","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0585","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0590","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1038\/leu.2017.152","article-title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth","volume":"31","author":"Delgado-Calle","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0595","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1074-7613(00)80145-4","article-title":"Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis","volume":"11","author":"Shirogane","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0600","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/onc.2008.123","article-title":"Pim kinase-dependent inhibition of c-Myc degradation","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0605","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-08-0634","article-title":"Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels","volume":"68","author":"Morishita","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034736","article-title":"Activation of cell cycle arrest and apoptosis by the proto-oncogene Pim-2","volume":"7","author":"Levy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0615","doi-asserted-by":"crossref","first-page":"43220","DOI":"10.18632\/oncotarget.9215","article-title":"Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells","volume":"7","author":"Santio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0620","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/leu.2014.147","article-title":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma","volume":"29","author":"Hiasa","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0625","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.14388","article-title":"Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma","volume":"180","author":"Teramachi","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0630","article-title":"TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma","author":"Teramachi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jdsr.2021.08.006_bib0635","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.CAN-15-1703","article-title":"Bidirectional notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma","volume":"76","author":"Delgado-Calle","year":"2016","journal-title":"Cancer Res"}],"container-title":["Japanese Dental Science Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1882761621000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1882761621000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:44:43Z","timestamp":1761821083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1882761621000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":127,"alternative-id":["S1882761621000235"],"URL":"https:\/\/doi.org\/10.1016\/j.jdsr.2021.08.006","relation":{},"ISSN":["1882-7616"],"issn-type":[{"value":"1882-7616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis and treatment of multiple myeloma bone disease","name":"articletitle","label":"Article Title"},{"value":"Japanese Dental Science Review","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdsr.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}